Caveat in Chinese trial was the increased symptomatic intracranial hemorrhage risk ...

In a multicenter randomized trial, tenecteplase did not improve vision recovery compared with aspirin when given within 4.5 hours of acute central retinal artery occlusion (CRAO). The ...

Central retinal artery occlusion (CRAO) is an ophthalmic emergency that usually leads to sudden and permanent blindness, and ...

Intravenous tenecteplase administered within 4.5 hours after onset of central retinal artery occlusion does not improve vision recovery at 30 days compared with oral aspirin, according to a study ...

Central retinal artery occlusion can result in permanent vision loss. Effective treatment is lacking. We conducted a phase 3, double-blind, double-dummy, randomized, controlled trial involving ...

Recent research has revealed compelling evidence supporting tenecteplase as a more effective treatment for ischemic strokes compared to traditional alteplase therapy. This discovery could mark a major ...

PHOENIX -- Selected stroke patients did not benefit clinically from having the window of tenecteplase therapy extended beyond the first few hours of stroke onset, the randomized TIMELESS trial found.

Among patients with non–large vessel occlusion acute ischemic stroke and salvageable brain tissue, intravenous tenecteplase, a modified human tissue plasminogen activator, administered 4.5 to 24 hours ...

"This was a pivotal trial in establishing the safety and efficacy of tenecteplase as an alternative to alteplase in the thrombolytic treatment of acute ischemic stroke within 4.5 hours in Asian ...

Ischemic strokes occur when there is blocked blood flow to the brain, something that can result in permanent disability. Doctors can use certain medications to dissolve blood clots when they are the ...

Please provide your email address to receive an email when new articles are posted on . The findings were presented in a poster at the American College of Allergy, Asthma & Immunology Annual ...

Intravenous tenecteplase does not improve vision recovery and is associated with greater incidence of adverse events ...